Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIT-013 in Moderately Active Rheumatoid Arthritis
NCT06567470Phase 2Completed
- Sponsor
- Citryll
- Start
- Jul 2025
- Primary completion
- Jul 2026
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of CIT013 in rheumatoid arthritis (RA), sponsored by Citryll. Started Jul 2025; status: completed.
02
Drugs
CIT013
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06567470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06567470.